Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma
Sally Moore(University College Hospital), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Steve Schey(King's College London), Santosh Narat, Iftekhar Khan(Bayhealth Foundation), Matthew Streetly(King's College - North Carolina), Laura Percy(University College Hospital), Sajitha Sachchithanantham(The Royal Free Hospital), Sangeeta Atwal(King's College - North Carolina), Shirley D’Sa(University College Hospital), Neil Rabin(University College Hospital), Rosalynd Johnston(Royal Sussex County Hospital)
Cited by 14
Related Papers
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|386
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
|Journal of Clinical Oncology|2004|315
Guidelines for the diagnosis and management of multiple myeloma 2011
|British Journal of Haematology|2011|305